# Pralidoxime

## Pampara inj 500mg/20mL

| 藥物代碼 | IPAM2 |
| :--- | :--- |
| 適應症 | Treatment of muscle weakness and/or respiratory depression secondary to poisoning due to organophosphate anticholinesterase pesticides and chemicals \(eg, nerve agents\); control of overdose of anticholinesterase medications used to treat myasthenia gravis \(ambenonium, neostigmine, pyridostigmine\) |
| 副作用 | Cardiovascular: Cardiac arrest, hypertension, tachycardiaCentral nervous system: Dizziness, drowsiness, headache, paralysis, seizureDermatologic: Skin rashGastrointestinal: Nausea Hepatic: Increased serum ALT \(transient\), increased serum AST \(transient\)Local: Pain at injection site \(IM\)Neuromuscular & skeletal: Fasciculations, increased creatine phosphokinase, laryngospasm, muscle rigidity, weaknessOphthalmic: Accommodation disturbance, blurred vision, diplopiaRenal: Renal insufficiencyRespiratory: Apnea, hyperventilation |
| 禁忌 | According to the manufacturer, relative contraindications include hypersensitivity to pralidoxime or any component of the formulation and other situations where the risk of administration clearly outweighs possible benefit. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Adult 500 mg-1 g slow IV injection Children 20-40 mg/kg slow IV injection |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Hold Breast Feeding 暫停哺乳 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【N/S】 可選 |
| IVP 用法建議 | slow injection |
| IVD 用法建議 | 以10~20 mg/mL 滴注 15~30 min,Max: 200 mg/min |
| 注意事項 | Intravenous 1.dilute to a final concentration of 10 to 20 mg/mL in NS; infuse over 15 to 30 minutes 2.maximum infusion rate is 200 mg/min |

